Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Valsartan 0.25 mg/kg
Valsartan 1.0 mg/kg
Valsartan 4.0 mg/kg
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Children, pediatrics, High Blood Pressure, Hypertension, Valsartan
Eligibility Criteria
Inclusion Criteria:
- Children aged 6 months - 5 years at Visit 1, with a documented history of hypertension
- Must be able to swallow liquid formulation
- Must be ≥ 6 kg or ≤ 40 kg at randomization
- Must have documented history MSSBP (mean of 3 measurements) must be ≥ 95th percentile for age, gender and height, at randomization
- If patients enter with uncontrolled BP they can remain on background antihypertensives with an unchanged dosing regimen
- If patients have had a solid organ transplant more than 1 year ago they must be on stable doses of immunosuppressive therapy
- Parent(s)/guardian(s) are able to follow verbal and/or written instructions in the local language
Exclusion Criteria:
- Patients with background ARB therapy
- Patients demonstrating any clinically significant abnormalities or clinically noteworthy abnormal lab values (other than those relating to renal function)
- AST/SGOT or ALT/SGPT > 3 times the upper limit of the reference range
- Glomerular filtration rate < 30 mL/min/1.73m²
- Serum potassium > upper limit of the reference range
- MSSBP ≥ 25% above the 95th percentile
- Patients exhibiting clinically significant ECG abnormalities
- Patients that have coarctation of the aorta with a gradient of ≥ 30 mm Hg, or renal artery stenosis
Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- Sites in USA
- Sites in Belgium
- Sites in Brazil
- Sites in France
- Sites in Hungary
- Sites in India
- sites in Italy
- Sites in Poland
- Sites in South Africa
- Sites in Sweden
- Sites in Turkey
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Low Dose
Medium Dose
High Dose
Arm Description
Outcomes
Primary Outcome Measures
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)
Secondary Outcome Measures
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)
Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)
Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)
Full Information
NCT ID
NCT00435162
First Posted
February 13, 2007
Last Updated
April 15, 2011
Sponsor
Novartis Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT00435162
Brief Title
Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure
Official Title
A Randomized, Multicenter, Double-blind, 6 Week Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 6 Months - 5 Years Old With Hypertension, Followed by a 2 Week Placebo Withdrawal Period.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2011
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
January 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Novartis Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of three doses of valsartan (0.25, 1.0, and 4.0 mg/kg) on mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) in 6 months - 5 year old children with hypertension (sitting systolic blood pressure [SSBP] ≥ 95th percentile ).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Children, pediatrics, High Blood Pressure, Hypertension, Valsartan
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
74 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low Dose
Arm Type
Experimental
Arm Title
Medium Dose
Arm Type
Experimental
Arm Title
High Dose
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Valsartan 0.25 mg/kg
Intervention Description
once daily
Intervention Type
Drug
Intervention Name(s)
Valsartan 1.0 mg/kg
Intervention Description
once daily
Intervention Type
Drug
Intervention Name(s)
Valsartan 4.0 mg/kg
Intervention Description
once daily
Primary Outcome Measure Information:
Title
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)
Time Frame
baseline and week 6
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)
Time Frame
baseline and week 6
Title
Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)
Time Frame
week 6 and week 8
Title
Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)
Time Frame
week 6 and week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children aged 6 months - 5 years at Visit 1, with a documented history of hypertension
Must be able to swallow liquid formulation
Must be ≥ 6 kg or ≤ 40 kg at randomization
Must have documented history MSSBP (mean of 3 measurements) must be ≥ 95th percentile for age, gender and height, at randomization
If patients enter with uncontrolled BP they can remain on background antihypertensives with an unchanged dosing regimen
If patients have had a solid organ transplant more than 1 year ago they must be on stable doses of immunosuppressive therapy
Parent(s)/guardian(s) are able to follow verbal and/or written instructions in the local language
Exclusion Criteria:
Patients with background ARB therapy
Patients demonstrating any clinically significant abnormalities or clinically noteworthy abnormal lab values (other than those relating to renal function)
AST/SGOT or ALT/SGPT > 3 times the upper limit of the reference range
Glomerular filtration rate < 30 mL/min/1.73m²
Serum potassium > upper limit of the reference range
MSSBP ≥ 25% above the 95th percentile
Patients exhibiting clinically significant ECG abnormalities
Patients that have coarctation of the aorta with a gradient of ≥ 30 mm Hg, or renal artery stenosis
Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Sponsor GmbH
Official's Role
Study Director
Facility Information:
Facility Name
Sites in USA
City
USA
State/Province
New Jersey
Country
United States
Facility Name
Sites in Belgium
City
Belgium
Country
Belgium
Facility Name
Sites in Brazil
City
Brazil
Country
Brazil
Facility Name
Sites in France
City
Paris
Country
France
Facility Name
Sites in Hungary
City
Hungary
Country
Hungary
Facility Name
Sites in India
City
India
Country
India
Facility Name
sites in Italy
City
Italy
Country
Italy
Facility Name
Sites in Poland
City
Poland
Country
Poland
Facility Name
Sites in South Africa
City
South Africa
Country
South Africa
Facility Name
Sites in Sweden
City
Sweden
Country
Sweden
Facility Name
Sites in Turkey
City
Turkey
Country
Turkey
12. IPD Sharing Statement
Learn more about this trial
Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure
We'll reach out to this number within 24 hrs